Overview

Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure control with one or two antiepileptics (AEDs).
Phase:
Phase 3
Details
Lead Sponsor:
SK Life Science
SK Life Science, Inc.